Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Regeneron 4Q and FY20 Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Regeneron 4Q and FY20 Results

REGEN-COV antibody cocktail for COVID-19 received FDA EUA; Net sales of REGEN-COV were $146 million in the quarter and $186 million for the year.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron
4Q Revenues: $2.4 billion (+30%)
4Q Earnings: $1.1 billion (+5%)
YTD Revenues: $8.5 billion (+30%)
YTD Earnings: $3.5 billion (+66%)
Comments: EYLEA U.S. sales increased 10% to $1.3 billion in the quarter. Full year EYLEA sales in the U.S. increased to $4.9 billion, up 7%. Dupixent global sales, which are recorded by Sanofi, increased 56% to $1.17 in the quarter. REGEN-COV antibody cocktail for COVID-19 received FDA Emergency Use Authorization. Regeneron signed an agreement with U.S. government to purchase up to 1.25 million additional doses. Net product sales of REGEN-COV were $146 million in the quarter and $186 million for the full year.

Total revenues also include Sanofi and Bayer collaboration revenues of $678 million in the quarter and $2.4 billion for the year. Sanofi collaboration revenue increased primarily due to the Company’s share of profits from commercialization of antibodies, which were $230 million and $785 million in the quarter and full year, respectively, compared to $104 million and $209 million in 4Q and FY19, respectively. R&D expenses were up 35% to $745 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters